Market Access
The World’s Most Expensive Drug
Priced at a staggering $2.125 million per patient, Zolgensma is now the world’s most ...
The Why and How of Hub Services
When it comes to conducting benefits investigations, initiating prior authorizations, and accomplishing other patient ...
Changes to Medicare Part D Continue to Evolve
With the Bipartisan Budget Act of 2018 (BBA), Congress made changes to the Medicare ...
The Challenges of Outcomes-Based Contracting and What Can Be Done About It
Drug prices in America are high. Of course, putting that into the right context ...
Endangered PBMs’ Best Option for the Future
Pharmacy benefit managers (PBMs) have been under fire for some time now. Many of ...
Is the Digital Health Formulary a Rising Tide?
One of the earliest formularies on record is the 1816 Pharmacopoeia of the New York ...
How Safe are Safe Harbor Regulations?
The phrase “no more rebates” and recent guidance from the Department of Health and ...
Drug Pricing Regulatory Action Near Certain
It is never a good sign when reputational polls show that your industry ranks ...
Hub Services Offer Big Benefits for Retail Launch Brands
Along with their specialty brand counterparts, retail brands are starting to experience the pain ...
One PBM Executive’s Reaction to Recent Hearings on Capitol Hill
Earlier this month, top executives from pharmacy benefit managers (PBMs) Express Scripts, CVS Caremark, ...
Dealing with Insurers’ Copay Accumulators
Over the past couple of years, more and more insurers have started to implement ...
The Scrutiny on Rebates and Prices Will Change the Pharma-Payer Relationship
The government is the largest payer in the U.S. through Medicare and Medicaid, and ...
Four Key Questions About Payer Strategies in 2019
PM360 asked those with expertise in payer strategies how changes are impacting pharma’s relationship ...
